

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



February 06, 2020

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051  
**NSE Code – SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**BSE Code – 524715**

Dear Sirs,

**Sub: Unaudited Financial Results for the quarter and nine months ended December 31, 2019 and declaration of an Interim Dividend**

1. We enclose herewith the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2019 which have been approved and taken on record at the meeting of the Board of Directors of the Company held today, along with the Limited Review Report of the Statutory Auditors of the Company on Standalone and Consolidated Unaudited Financial Results.
2. We inform you that the Board of Directors of the Company at its meeting held today declared the Interim Dividend of Rs. 3.00/- (Rupees Three Only) per equity share of Re. 1 each for the financial year 2019-20

We further inform you that, the Board of Directors of the Company has fixed the Record Date as Tuesday, February 18, 2020 to determine the names of the equity shareholders, who shall be entitled to receive payment towards Interim Dividend of the Company for the financial year 2019-20 declared today. The payment of the interim dividend would be made to the eligible shareholders on or before February 24, 2020.

The meeting of the Board of Directors of the Company commenced at 10:45 a.m. and concluded at 02:40 p.m.

Thanking you,

Yours faithfully,  
**For Sun Pharmaceutical Industries Ltd.**

**Ashok I. Bhuta**  
**Sr. GM - Secretarial &**  
**Compliance Officer**

**Encl: As above**

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Sun Pharmaceutical Industries Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharmaceutical Industries Limited (the "Company") for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003



per Paul Alvares  
Partner  
Membership No.: 105754



UDIN: 20105754AAAAAD71105

Mumbai  
February 06, 2020



**Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended December 31, 2019**

(₹ in Crore)

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from operations						
a. Revenue from contracts with customers	2,920.83	3,215.01	2,192.41	9,156.33	7,525.49	9,783.29
b. Other operating revenues	92.72	158.28	68.85	539.52	225.59	519.92
<b>Total revenue from operations (I)</b>	<b>3,013.55</b>	<b>3,373.29</b>	<b>2,261.26</b>	<b>9,695.85</b>	<b>7,751.08</b>	<b>10,303.21</b>
II Other income	15.36	258.33	27.76	292.27	592.21	1,271.44
III <b>Total income (I+II)</b>	<b>3,028.91</b>	<b>3,631.62</b>	<b>2,289.02</b>	<b>9,988.12</b>	<b>8,343.29</b>	<b>11,574.65</b>
IV <b>Expenses</b>						
Cost of materials consumed	947.21	793.57	716.27	2,434.59	1,796.52	2,727.71
Purchases of stock-in-trade	303.12	309.16	329.73	908.53	982.45	1,196.85
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(145.17)	114.58	(64.65)	44.32	(69.66)	(251.30)
Employee benefits expense	423.97	432.77	391.20	1,283.43	1,145.34	1,571.34
Finance costs	98.76	114.47	133.38	270.48	421.55	540.92
Depreciation and amortisation expense	144.40	139.14	134.06	419.12	420.77	552.95
Other expenses	825.04	858.04	756.17	2,580.13	2,289.42	3,089.31
Net (gain) / loss on foreign currency transactions	(46.43)	30.26	(42.07)	(38.26)	409.25	213.04
<b>Total expenses (IV)</b>	<b>2,550.90</b>	<b>2,791.99</b>	<b>2,354.09</b>	<b>7,902.34</b>	<b>7,395.64</b>	<b>9,640.82</b>
V <b>Profit / (Loss) before exceptional item and tax (III-IV)</b>	<b>478.01</b>	<b>839.63</b>	<b>(65.07)</b>	<b>2,085.78</b>	<b>947.65</b>	<b>1,933.83</b>
VI Exceptional item (Refer Note 4)	-	-	-	-	1,214.38	1,214.38
VII <b>Profit / (Loss) before tax (V-VI)</b>	<b>478.01</b>	<b>839.63</b>	<b>(65.07)</b>	<b>2,085.78</b>	<b>(266.73)</b>	<b>719.45</b>
VIII Tax expense / (credit)	9.25	16.47	(26.39)	30.49	(15.27)	(97.15)
IX <b>Profit / (Loss) for the period (VII-VIII)</b>	<b>468.76</b>	<b>823.16</b>	<b>(38.68)</b>	<b>2,055.29</b>	<b>(251.46)</b>	<b>816.60</b>
X <b>Other comprehensive income (OCI)</b>						
a. (i) Items that will not be reclassified to profit or loss	6.56	(26.42)	(2.66)	(26.39)	12.08	11.29
(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.29)	9.23	0.93	9.22	(4.22)	(3.95)
b. (i) Items that may be reclassified to profit or loss	(33.04)	(26.26)	(31.92)	(65.32)	252.47	271.15
(ii) Income tax relating to items that may be reclassified to profit or loss	11.54	9.17	(27.57)	22.82	(12.27)	(94.75)
<b>Total other comprehensive income (a+b) (X)</b>	<b>(17.23)</b>	<b>(34.28)</b>	<b>(61.22)</b>	<b>(69.67)</b>	<b>248.06</b>	<b>183.74</b>
XI <b>Total comprehensive income for the period (IX+X)</b>	<b>451.53</b>	<b>788.88</b>	<b>(99.90)</b>	<b>1,995.62</b>	<b>(3.40)</b>	<b>1,000.34</b>
XII Paid-up equity share capital - face value ₹ 1 each	239.93	239.93	239.93	239.93	239.93	239.93
XIII Other equity						22,603.68
XIV <b>Earnings per equity share of ₹ 1 each (not annualised for quarters)</b>						
₹ (Basic)	1.95	3.43	(0.16)	8.57	(1.05)	3.40
₹ (Diluted)	1.95	3.43	(0.16)	8.57	(1.05)	3.40
See accompanying notes to the unaudited standalone financial results						
Research and development expenses incurred (included above)	246.87	249.42	250.17	718.10	699.18	954.25




**SIGNED FOR IDENTIFICATION**  
BY  
  
**S R B C & CO LLP**  
**MUMBAI**

**Notes:**

- 1 The above unaudited standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 05, 2020 and February 06, 2020.
- 2 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3 Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", and applied to all lease contracts existing on April 01, 2019 using the modified retrospective method. Accordingly, the Company has recognised a lease liability measured at the present value of the remaining lease payments, and right-of-use (ROU) asset at an amount equal to lease liability (adjusted for any related prepayments). The impact on the profit and earnings per share for the quarter ended and nine months ended is not material.
- 4 The Company had entered into settlement agreements with Apotex Corporation, Retailer Purchasers, end-payor plaintiffs and Direct Purchaser Plaintiffs in respect of an antitrust litigation, relating to a product Modafinil. The Company had accounted for an amount of ₹ 950.50 Crore and ₹ 1,238.38 Crore in the year ended on March 31, 2018 and March 31, 2019 respectively out of which ₹ 950.50 Crore and ₹ 1,214.38 Crore were disclosed as exceptional item. During nine months ended December 31, 2019, the Company has entered into a settlement agreement with the last remaining Plaintiff and the settlement amount has been grouped in other expenses.
- 5 The Board of Directors at its meeting held on February 06, 2020, have declared for the year 2019-2020, an interim dividend of ₹ 3 per equity share of ₹ 1 each. The record date fixed for the purpose of ascertaining the entitlement is February 18, 2020.
- 6 The Company has only one reportable segment namely 'Pharmaceuticals'.
- 7 Figures for previous periods have been regrouped / reclassified wherever considered necessary.

For and on behalf of the Board



Dillip S. Shanghvi  
Managing Director

Mumbai, February 6, 2020





Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Sun Pharmaceutical Industries Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sun Pharmaceutical Industries Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint venture for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Sun Pharmaceutical Industries Limited  
Independent Auditor's Review Report  
Page 2 of 4

6. The accompanying Statement includes unaudited interim financial information and other unaudited financial information of 26 subsidiaries including an associate and a joint venture, whose interim financial information, without giving effect to elimination of intra-group transactions, reflect for subsidiaries; Group's share of total revenues of INR 3,015.96 Crore and INR 10,165.51 Crore, Group's share of total net loss after tax of INR 820.53 Crore and INR 1,492.22 Crore, Group's share of total comprehensive loss of INR 650.50 Crore and INR 1,498.67 Crore, for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019, respectively, as considered in the Statement, which have been reviewed by their respective independent auditors. The independent auditor's reports on interim financial information of these entities have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries, joint venture and associates is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For SRBC & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003

per Paul Alvarez  
Partner  
Membership No.: 105754



UDIN: 20105754AAAAAC1197

Mumbai  
February 06, 2020



Sun Pharmaceutical Industries Limited  
Independent Auditor's Review Report  
Page 3 of 4

Annexure I - List of entities included in Limited review report

Sr.No	Name of the entity
	Subsidiaries:
1	Ranbaxy Pharmacie Generiques
2	Office Pharmaceutique Industriel Et Hospitalier
3	Zenotech Laboratories Limited (consolidated)
4	Ranbaxy (U.K.) Limited
5	Ranbaxy Holdings (U.K.) Limited
6	Ranbaxy Ireland Limited
7	Basics GmbH
8	Sun Pharma Laboratorios S.L.U (formerly known as Laboratorios Ranbaxy, S.L.U.)
9	Ranbaxy Italia S.P.A.
10	Sun Pharma (Netherlands) B.V. (Formerly known as Ranbaxy (Netherlands) B.V.)
11	Ranbaxy (Poland) SP. Z O.O.
12	AO Ranbaxy
13	"Ranbaxy Pharmaceuticals Ukraine" LLC
14	Terapia SA
15	Ranbaxy South Africa (Pty) Ltd (consolidated)
16	Ranbaxy Nigeria Limited
17	Ranbaxy Pharmaceuticals (Pty) Ltd
18	Sun Pharmaceuticals Morocco LLC
19	Sun Pharma Egypt Limited LLC (Formerly Known as Ranbaxy Egypt Ltd)
20	Rexcel Egypt LLC
21	Ranbaxy (Malaysia) SDN. BHD.
22	Sun Pharma ANZ Pty Ltd
23	Sun Pharmaceuticals Holdings USA, Inc. (consolidated)
24	Ranbaxy Farmaceutica Ltda.
25	Sun Pharmaceutical Peru S.A.C.
26	Sun Pharma Canada Inc. (Formerly known as Ranbaxy Pharmaceuticals Canada Inc.)
27	Ranbaxy (Thailand) Co., Ltd.
28	JSC Biosintez
29	Faststone Mercantile Company Private Limited
30	Green Eco Development Centre Limited
31	Neetnav Real Estate Private Limited
32	Realstone Multitrade Private Limited
33	Skisen Labs Private Limited
34	Softdeal Trading Company Private Ltd
35	Universal Enterprises Private Limited
36	Sun Pharmaceutical (Bangladesh) Limited
37	Sun Pharmaceuticals Germany GmbH
38	Sun Pharmaceuticals France



Sun Pharmaceutical Industries Limited  
Independent Auditor's Review Report  
Page 4 of 4

Sr.No	Name of the entity
39	Sun Pharma Switzerland Ltd.
40	Sun Pharmaceutical Industries (Europe) B.V.
41	OOO "Sun Pharmaceutical Industries" Limited
42	Alkaloida Chemical Company Zrt.
43	Sun Pharmaceuticals SA (Pty) Ltd
44	Sun Pharma Holdings
45	Aditya Acquisition Company Ltd.
46	Taro Pharmaceutical Industries Ltd (TARO) (consolidated)
47	Sun Global Development FZE
48	Sun Pharma Global FZE
49	Sun Pharma Healthcare FZE
50	Sun Laboratories FZE
51	Sun Pharma East Africa Limited
52	Sun Pharma Philippines, Inc.
53	Sun Pharma Japan Ltd.
54	Sun Pharmaceuticals Korea Ltd.
55	Sun Pharmaceutical Industries (Australia) Pty Limited
56	Sun Farmaceutica do Brasil Ltda.
57	Sun Pharmaceutical Peru S.A.C.
58	SPIL De Mexico S.A. DE C.V.
59	Sun Pharma De Mexico S.A. DE C.V.
60	Sun Pharma De Venezuela, C.A.
61	Sun Global Canada Pty. Ltd.
62	Sun Pharma Laboratories Limited
63	Sun Pharmaceutical Medicare Limited
64	Caraco Pharmaceuticals Private Limited
65	Pola Pharma Inc. (consolidated)
66	Sun Pharma Distributors Limited
	Joint Venture:
1	Artes Biotechnology GmbH
	Associates:
1	Medinstill LLC
2	Generic Solar Power LLP
3	Trumpcard Advisors and Finvest LLP
4	Tarsius Pharma Ltd.





**Sun Pharmaceutical Industries Limited**

Registered Office: Sun Pharma Advanced Research Centre, Tandajja, Vadodara - 390012.  
Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.  
CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2019**

(₹ In Crore)

Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I Revenue from operations</b>						
a. Revenue from contracts with customers	8,038.65	7,949.19	7,656.71	24,247.14	21,642.02	28,686.28
b. Other operating revenues	116.20	174.16	83.48	405.42	259.97	379.63
<b>Total revenue from operations (I)</b>	<b>8,154.85</b>	<b>8,123.35</b>	<b>7,740.19</b>	<b>24,652.56</b>	<b>21,901.99</b>	<b>29,065.91</b>
<b>II Other income</b>	<b>119.88</b>	<b>200.85</b>	<b>193.06</b>	<b>533.75</b>	<b>743.96</b>	<b>1,025.49</b>
<b>III Total income (I+II)</b>	<b>8,274.73</b>	<b>8,324.20</b>	<b>7,933.25</b>	<b>25,186.31</b>	<b>22,645.95</b>	<b>30,091.40</b>
<b>IV Expenses</b>						
Cost of materials consumed	1,495.77	1,474.05	1,432.97	4,305.65	3,716.16	5,782.70
Purchases of stock-in-trade	842.37	851.13	721.51	2,503.73	2,321.76	2,519.38
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(138.15)	(57.32)	11.18	116.26	(7.74)	(433.11)
Employee benefits expense	1,549.12	1,620.94	1,494.98	4,710.46	4,398.30	5,967.09
Finance costs	62.96	83.93	144.79	250.95	405.22	555.25
Depreciation and amortisation expense	546.99	473.28	471.05	1,477.40	1,299.20	1,753.25
Other expenses	2,646.14	2,453.31	2,153.84	7,547.39	6,144.36	8,829.06
Net (gain) / loss on foreign currency transactions	(81.80)	(8.50)	(227.18)	(157.68)	38.35	93.20
<b>Total expenses (IV)</b>	<b>6,923.40</b>	<b>6,890.82</b>	<b>6,203.14</b>	<b>20,754.16</b>	<b>18,315.61</b>	<b>25,066.82</b>
<b>V Profit before exceptional item and tax (III-IV)</b>	<b>1,351.33</b>	<b>1,433.38</b>	<b>1,730.11</b>	<b>4,432.15</b>	<b>4,330.34</b>	<b>5,024.58</b>
<b>VI Exceptional item (Refer Note 4)</b>	-	-	-	-	1,214.38	1,214.38
<b>VII Profit before tax (V-VI)</b>	<b>1,351.33</b>	<b>1,433.38</b>	<b>1,730.11</b>	<b>4,432.15</b>	<b>3,115.96</b>	<b>3,810.20</b>
<b>VIII Tax expense for period / year</b>	<b>327.62</b>	<b>266.03</b>	<b>270.92</b>	<b>739.71</b>	<b>629.69</b>	<b>600.88</b>
<b>IX Profit for the period before share of profit / (loss) of associates and joint ventures (VII-VIII)</b>	<b>1,023.71</b>	<b>1,167.35</b>	<b>1,459.19</b>	<b>3,692.44</b>	<b>2,486.27</b>	<b>3,209.32</b>
<b>X Share of profit / (loss) of associates and joint ventures (net)</b>	<b>(4.33)</b>	<b>(4.18)</b>	<b>1.84</b>	<b>(13.24)</b>	<b>0.98</b>	<b>(1.46)</b>
<b>XI Net Profit after taxes and share of profit / (loss) of associates and joint ventures but before non-controlling interests (IX+X)</b>	<b>1,019.38</b>	<b>1,163.17</b>	<b>1,461.03</b>	<b>3,679.20</b>	<b>2,487.25</b>	<b>3,207.86</b>
Non-controlling interests	105.86	99.08	219.18	314.11	457.71	542.44
<b>XII Net Profit after taxes, share of profit / (loss) of associates and joint ventures and non-controlling interests</b>	<b>913.52</b>	<b>1,064.09</b>	<b>1,241.85</b>	<b>3,365.09</b>	<b>2,029.54</b>	<b>2,665.42</b>
<b>XIII Other comprehensive income (OCI)</b>						
A. (i) Items that will not be reclassified to profit or loss	178.68	(117.89)	(179.89)	(37.50)	(58.90)	23.96
(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.07)	13.11	2.42	12.96	(5.39)	(6.25)
B. (i) Items that may be reclassified to profit or loss	274.92	610.53	(1,890.82)	876.73	1,858.69	1,756.69
(ii) Income tax relating to items that may be reclassified to profit or loss	11.03	8.73	(23.09)	19.96	(8.87)	(94.41)
<b>Total other comprehensive income (A+B) (XIII)</b>	<b>461.56</b>	<b>514.48</b>	<b>(2,091.38)</b>	<b>872.15</b>	<b>1,785.53</b>	<b>1,679.99</b>
<b>XIV Total comprehensive income for the period (XI+XIII)</b>	<b>1,480.94</b>	<b>1,677.65</b>	<b>(630.35)</b>	<b>4,551.35</b>	<b>4,272.78</b>	<b>4,887.85</b>
Attributable to:						
- Owners of the Company	1,355.93	1,499.33	(539.76)	4,137.22	3,695.55	4,205.41
- Non-controlling interests	125.01	178.32	(90.59)	414.13	577.23	682.44
<b>XV Paid-up equity share capital - face value ₹ 1 each</b>	<b>239.93</b>	<b>239.93</b>	<b>239.93</b>	<b>239.93</b>	<b>239.93</b>	<b>239.93</b>
<b>XVI Other equity</b>						<b>41,169.13</b>
<b>XVII Earnings per equity share of ₹ 1 each (not annualised for quarters)</b>						
₹ (Basic)	3.81	4.43	5.18	14.03	8.46	11.11
₹ (Diluted)	3.81	4.43	5.18	14.03	8.46	11.11
See accompanying notes to the unaudited consolidated financial results						
Research and development expenses incurred (included above)	518.04	479.96	451.54	1,404.66	1,378.01	1,912.87

**SIGNED FOR IDENTIFICATION**  
BY *SR*  
**S R B C & CO LLP**  
**MUMBAI**



**Sun Pharmaceutical Industries Limited**

Registered Office: Sun Pharma Advanced Research Centre, Tandajla, Vadodara - 390012.  
Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.  
CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

**Notes :**

- 1 The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 05, 2020 and February 06, 2020.
- 2 These unaudited consolidated financial results relate to Sun Pharmaceutical Industries Limited (SPIL), its Subsidiaries (together constitute 'the Group'), Joint Ventures and Associates and are prepared by applying Ind AS 110 - "Consolidated Financial Statements", and Ind AS 28 - "Investments in Associates and Joint Ventures".
- 3 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 4 The Company had entered into settlement agreements with Apotex Corporation, Retailer Purchasers, end-payor plaintiffs and Direct Purchaser Plaintiffs in respect of an antitrust litigation, relating to a product Modafinil. The Company had accounted for an amount of ₹ 950.50 Crore and ₹ 1,238.38 Crore in the year ended on March 31, 2018 and March 31, 2019 respectively out of which ₹ 950.50 Crore and ₹ 1,214.38 Crore were disclosed as exceptional item. During Nine months ended December 31, 2019, the Company has entered into a settlement agreement with the last remaining Plaintiff and the settlement amount has been grouped in other expenses.
- 5 Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", and applied to all lease contracts existing on April 01, 2019 using the modified retrospective method. Accordingly, the Company has recognised a lease liability measured at the present value of the remaining lease payments, and right-of-use (ROU) asset at an amount equal to lease liability (adjusted for any related prepayments). The impact on the profit and earnings per share for the Quarter ended and Nine months ended is not material.
- 6 Pola Pharma Inc. Japan became a step down subsidiary of the Company with effect from January 01, 2019. Accordingly, the results for the Quarter and Nine months ended includes results of Pola Pharma Inc., and hence are not comparable with Quarter and Nine months ended December 31, 2018.
- 7 The Board of Directors at its meeting held on February 06, 2020, have declared for the year 2019-2020, an interim dividend of ₹ 3 per equity share of ₹ 1 each. The record date fixed for the purpose of ascertaining the entitlement is February 18, 2020.
- 8 The Group has only one reportable segment namely 'Pharmaceuticals'.
- 9 Figures for previous periods have been regrouped / reclassified wherever considered necessary.

For and on behalf of the Board



**Dilip S. Shanghvi**  
Managing Director

Mumbai, February 06, 2020

